Abstract
Amphotericin B (1), produced by Streptomyces nodosus, is a medically important antifungal that is also active against Leishmania parasites. However, its use is severely limited by its toxicity. Genetic disruption of one of the post PKS genes encoding a cytochrome P450 produces 2, which has been shown to be less toxic and retains antifungal activity. We report here improved production and purification protocols involving the intermediacy of a less polar Fmoc derivative. Development of this methodology will enable the production of gram quantities of these metabolites for extensive biological assays and assist with investigations into the mode of action of these antibiotics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
